Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 4/20 | 0.56 |
| ▸ | PDE2A | O00408 | 10/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1332003 | 1.00 | METAP2 (0.56) | METAP2PDE2AEGLN2PDE3ALMNA | |
| SCHEMBL1333293 | 0.85 | METAP2 (0.58) | METAP2PDE2AEGLN2PDE3ALMNA | |
| SCHEMBL1331518 | 0.82 | METAP2 (0.57) | METAP2PDE2AEGLN2PDE3APREP | |
| SCHEMBL1333094 | 0.82 | METAP2 (0.57) | METAP2PDE2APDE3ALMNAKDM4E | |
| SCHEMBL1331962 | 0.82 | METAP2 (0.57) | METAP2PDE2AEGLN2PDE3A | |
| SCHEMBL1332422 | 0.82 | METAP2 (0.59) | METAP2PDE2ASMN1; SMN2 | |
| SCHEMBL1332488 | 0.81 | METAP2 (0.55) | METAP2PDE2AEGLN2PDE3APREP | |
| SCHEMBL1333351 | 0.81 | METAP2 (0.55) | METAP2PDE2APDE3ALMNASMN1; SMN2 | |
| SCHEMBL1333316 | 0.80 | METAP2 (0.55) | METAP2PDE2APDE3AKDM4EALDH1A1 | |
| SCHEMBL1333313 | 0.80 | METAP2 (0.55) | METAP2PDE2APDE3AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281859-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-17 | — | — | US | claimed |
| US-8546406-B2 | Heterocyclic compounds as metap-2 inhibitors | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546406-B2 | Heterocyclic compounds as metap-2 inhibitors | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20110281859-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-17 | — | — | US | disclosed |
| US-20110281859-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281859-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS | METAP2, METAP1, XPNPEP2 | METAP2 1/4885PDE2A 2740/4885EGLN2 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.